Méndez-Sánchez N

Idioma: Ingles.
Referencias bibliográficas: 25
Paginas: 53-55
Archivo PDF: 45.43 Kb.

FRAGMENTO

Sin resumen

REFERENCIAS (EN ESTE ARTÍCULO)

1. Mendez-Sanchez N, Motola-Kuba D, Chavez-Tapia NC, Bahena J, Correa-Rotter R, Uribe M. Prevalence of hepatitis C virus infection among hemodialysis patients at a tertiary-care hospital in Mexico City, Mexico. J Clin Microbiol 2004; 42: 43212. [PMID: 15365034]

2. Gonzalez-Michaca L, Soto-Ramirez LE, Rodriguez R, Gamba G. Viral hepatitis C in patients with terminal chronic renal insufficiency. III. Viral quantification. Rev Invest Clin 2001; 53: 21-7. [PMID: 11332047]

3. Casanovas-Taltavull T, Baliellas C, Benasco C, Serrano TT, Casanova A, Perez JL, Guerrero L, Gonzalez MT, Andres E, Gil-Vernet S, Casais LA. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. Am J Gastroenterol 2001; 96: 1170-7. [PMID: 11316166]

4. Medina J, Garcia-Buey L, Moreno-Otero R. Hepatitis C virusrelated extra-hepatic disease–aetiopathogenesis and management. Aliment Pharmacol Ther 2004; 20: 129-41. [PMID: 15233692]

5. Alric L, Plaisier E, Thebault S, Peron JM, Rostaing L, Pourrat J, Ronco P, Piette JC, Cacoub P. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis 2004; 43: 617-23. [PMID: 15042538]

6. Contreras AM, Vargas-Frutos E. Hepatitis viral C en patients con insuficiencia renal crónica, in Conceptos actuales en Hepatitis C, Mendez-Sanchez N, Uribe M, Editors. México: Mc Graw-Hill, 2005, p. 203–216.

7. Fabrizi F, Martin P, Bunnapradist S. Treatment of chronic viral hepatitis in patients with renal disease. Gastroenterol Clin North Am 2004; 33: 655-70, xi. [PMID: 15324949]

8. Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of antihepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000; 11: 1896-902. [PMID: 11004221]

9. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther 2004; 20: 1271-7. [PMID: 15606388]

10. Bruchfeld A, Wilczek H, Elinder CG. Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. Transplantation 2004; 78: 745-50. [PMID: 15371680]

11. Periera BJ, Wright TL, Schmid CH, Levey AS. The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation 1995; 60: 799-805. [PMID: 7482738]

12. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Metaanalysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 2003; 18: 1071-81. [PMID: 14653826]

13. Thevenot T, Regimbeau C, Ratziu V, Leroy V, Opolon P, Poynard T. Meta-analysis of interferon randomized trial in the treatment of viral hepatitis C in naive patients: 1999 update. J Viral Hepat 2001; 8: 48-62. [PMID: 11155152]

14. Russo MW, Goldsweig CD, Jacobson IM, Brown RS, Jr. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol 2003; 98: 1610-5. [PMID: 12873587]

15. Chen YK, Bala K. Treatment of chronic hepatitis C with recombinant interferon alfa. West J Med 1992; 156: 72. [PMID: 1734608]

16. Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, Miglioli M, Barbara L. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994; 107: 812-7. [PMID: 7521308]

17. Mousa DH, Abdalla AH, Al-Shoail G, Al-Sulaiman MH, Al-Hawas FA, Al-Khader AA. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc 2004; 36: 1831-4. [PMID: 15350490]

18. Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis 2003; 42: 631-57. [PMID: 14520615]

19. Sporea I, Sirli R, Golea O, Totolici C, Danila M, Popescu A. Peginterferon alfa 2a (40 kDa) in patients on chronic haemodialysis with chronic C hepatitis. Preliminary results. Rom J Gastroenterol 2004; 13: 99-102. [PMID: 15229772]

20. Potthoff A, Wiegand J, Luth JB, Wedemeyer H, Manns MP, Tillmann HL. Superiority of standard interferon-alpha2b compared to pegylated interferon-alpha2b (12 kDa) in a hemodialysis patient with chronic hepatitis C? Clin Nephrol 2005; 63: 232-5. [PMID: 15786827]

21. Mukherjee S, Gilroy RK, McCashland TM, Schafer DF. Pegylated interferon for recurrent hepatitis C in liver transplant recipients with renal failure: a prospective cohort study. Transplant Proc 2003; 35: 1478-9. [PMID: 12826198]

22. Teta D, Luscher BL, Gonvers JJ, Francioli P, Phan O, Burnier M. Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients. Nephrol Dial Transplant 2005; 20: 991-3. [PMID: 15741205]

23. Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, Thibault V, Cadranel JF, Bernard B, Opolon P, Coriat P, Bitker MO. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 257-63. [PMID: 9862875]

24. Fabrizi F, Lunghi G, Marai P, Marcelli D, Guarnori I, Raffaele L, Erba G, Pagano A, Locatelli F. Virological and histological features of hepatitis C virus (HCV) infection in kidney transplant recipients. Nephrol Dial Transplant 1996; 11: 159-64. [PMID: 8649626]

25. Jefferson JA, Johnson RJ. Treatment of hepatitis C-associated glomerular disease. Semin Nephrol 2000; 20: 286-92. [PMID: 10855938]